32 citations
,
July 2016 in “PubMed” 5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.
January 2025 in “Scholars Journal of Medical Case Reports” Quetiapine may cause hair loss.
May 2022 in “Reactions Weekly”
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
June 2026 in “Skin Appendage Disorders” GLP-1 receptor agonists may increase the risk of hair loss, especially non-scarring types, due to weight loss-related nutrient deficiencies.
19 citations
,
July 2005 in “Steroids” Testosterone increases 3α-androstanediol levels, which can be blocked by finasteride.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
111 citations
,
February 1991 in “Headache The Journal of Head and Face Pain” Valproate significantly improved headaches in two-thirds of patients.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
June 2026 in “Eurasian Journal of Medicine” Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
2 citations
,
January 2013 in “Yearbook of Urology” Finasteride may help treat recurrent priapism in children, but more research is needed.
June 2024 in “Drug and therapeutics bulletin” Finasteride can cause depression, suicidal thoughts, and lasting psychiatric and sexual issues.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
September 2024 in “International Journal of Contemporary Pediatrics” A multidisciplinary approach is crucial for treating complex cases of Rapunzel syndrome in children.
2 citations
,
December 2001 in “PubMed”
15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride doesn't affect erections much, but may decrease libido in men.
3 citations
,
September 2020 in “Journal of developmental and behavioral pediatrics/Journal of developmental & behavioral pediatrics” The document discusses a young boy with autism and early puberty but does not provide a conclusion on managing his behavior.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
January 2011 in “Yearbook of Endocrinology”
32 citations
,
October 2003 Spironolactone is better than placebo for reducing excessive hair growth in women, but its effectiveness for acne is unclear due to small study sizes.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
October 2022 in “Respiratory Medicine” Patients treated in Respiratory Intensive Care Units for COVID-19 are more likely to get mood disorders than those in other care settings.